Who are Acyclovir 5 percent (Perrigo)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VALACYCLOVIR, Valacyclovir (ZELITREX), Acyclovir (ACV), intravenous (IV) ganciclovir, Masked Oral Valacyclovir, acyclovir in ME-609 vehicle.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acyclovir-5-percent-perrigo.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acyclovir 5 percent (Perrigo) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acyclovir 5 percent (Perrigo) (Acyclovir 5 percent (Perrigo)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antiviral. Area: Infectious Disease / Virology.

phase 3 Nucleoside analog antiviral Viral DNA polymerase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Acyclovir 5 percent (Perrigo) (Acyclovir 5 percent (Perrigo)) — Padagis LLC. Acyclovir is a nucleoside analog that inhibits viral DNA polymerase, preventing herpes simplex virus and varicella-zoster virus from replicating.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acyclovir 5 percent (Perrigo) TARGET	Acyclovir 5 percent (Perrigo)	Padagis LLC	phase 3	Nucleoside analog antiviral	Viral DNA polymerase
VALACYCLOVIR	VALACYCLOVIR		marketed	Nucleoside analogue	Viral DNA polymerase	1995-01-01
Valacyclovir (ZELITREX)	Valacyclovir (ZELITREX)	Assistance Publique - Hôpitaux de Paris	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpesvirus)
Acyclovir (ACV)	Acyclovir (ACV)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleoside analog antiviral	Viral DNA polymerase (herpes simplex virus and varicella-zoster virus)
intravenous (IV) ganciclovir	intravenous (IV) ganciclovir	University of Oslo School of Pharmacy	marketed	Nucleoside analog antiviral	Viral DNA polymerase (CMV and herpes simplex virus)
Masked Oral Valacyclovir	Masked Oral Valacyclovir	NYU Langone Health	marketed	Nucleoside analog antiviral	Viral DNA polymerase (HSV and VZV)
acyclovir in ME-609 vehicle	acyclovir in ME-609 vehicle	Medivir	phase 3	nucleoside analog	viral DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog antiviral class)

Merck Sharp & Dohme LLC · 3 drugs in this class
Hoffmann-La Roche · 2 drugs in this class
Göteborg University · 2 drugs in this class
Estetra · 1 drug in this class
Padagis LLC · 1 drug in this class
MinaPharm Pharmaceuticals · 1 drug in this class
French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
NYU Langone Health · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Ain Shams University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acyclovir 5 percent (Perrigo) — Competitive Intelligence Brief. https://druglandscape.com/ci/acyclovir-5-percent-perrigo. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing